Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical WorkflowsBusiness Wire • 05/06/26
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?Zacks Investment Research • 04/30/26
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/28/26
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026Business Wire • 04/28/26
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?Zacks Investment Research • 04/27/26
Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision MedicineBusiness Wire • 04/23/26
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD MonitoringBusiness Wire • 04/15/26
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptSeeking Alpha • 04/14/26
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026Business Wire • 04/14/26
Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant CareBusiness Wire • 04/13/26
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWEBusiness Wire • 04/09/26